

<b>SUSPECT ADVERSE REACTION REPORT</b>	
TLM-2025-01456 (0), GT-TOLMAR, INC.-24GT053806	

## I. REACTION INFORMATION

1. PATIENT INITIALS (first, last)	1a. COUNTRY	2. DATE OF BIRTH			2a. AGE Years	3. SEX	4-6 REACTION ONSET			8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION
JGLZ	GUATEMALA	Day 19	Month Apr	Year 1956	69	Male	Day 29	Month Oct	Year 2024	
7+13 DESCRIBE REACTION(S) (including relevant tests/lab data) 1) Cardiorespiratory arrest (Cardio-respiratory arrest (10007617), Cardio-respiratory arrest (10007617)) Fatal 2) PAIN ON THE RIGHT SIDE OF THE FACE (Facial pain (10016059), Facial pain (10016059)) (29/Oct/2024 - ) - Not Recovered/Not Resolved/Ongoing 3) COLD SENSATION (Feeling cold (10016326), Feeling cold (10016326)) (30/Oct/2024 - ) - Not Recovered/Not Resolved/Ongoing 4) Lung pain (Lung pain (10083482), Pulmonary pain (10074693)) (/Mar/2025 - ) - Unknown										<input checked="" type="checkbox"/> PATIENT DIED <input checked="" type="checkbox"/> LIFE THREATENING <input type="checkbox"/> INVOLVED OR PROLONGED INPATIENT HOSPITALIZATION <input type="checkbox"/> RESULTS IN PERSISTENCE OR SIGNIFICANT DISABILITY/INCAPACITY <input type="checkbox"/> CONGENITAL ANOMALY <input type="checkbox"/> OTHER MEDICALLY IMPORTANT CONDITION
Cont..										

## II. SUSPECT DRUG(S) INFORMATION

14. SUSPECT DRUG(S)(include generic name) 1) Eligard® (Leuprolide acetate, Leuprolide acetate) (Suspect) (Injection)(Unknown)(Unknown)(Unknown)	Cont..	20. DID EVENT ABATE AFTER STOPPING DRUG? <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA  21. DID EVENT REAPPEAR AFTER REINTRODUCTION <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA (NA : Not Applicable)
15. DAILY DOSE(S) 1) (22.5 milligram(s), 1 in 3 Month) 2) (22.5 milligram(s), 1 in 3 Month)	Cont..	
16. ROUTE(S) OF ADMINISTRATION 1) Subcutaneous 2) Subcutaneous	Cont..	
17. INDICATION(S) FOR USE 1) Prostatic cancer [10036946 - Prostatic cancer]	Cont..	
18. THERAPY DATE(S) (from/to) (09-May-2025 - )	19. THERAPY DURATION	

## III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction) 1) ACID 200(CIPROFLOXACIN HYDROCHLORIDE)	Cont..
23. OTHER RELEVANT HISTORY (e.g. diagnostics, allergies, pregnancy with last month of period, etc.) 1) DRAINAGE IN RIGHT LUNG (10084562, Drainage) (22/May/2023 - ) (Continuing: No)	Cont..

## IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER Name : Tolmar, Inc 701 Centre Avenue Fort Collins, CO, 80526, UNITED STATES OF AMERICA debbie.maierhofer@tolmar.comand+1-4129158447	Study Information Study Name: NA EudraCT Number: Protocol No.: NA Center No.: Subject Id :
24. REPORT NULLIFIED <input type="checkbox"/> YES <input type="checkbox"/> NO	24b. MFR CONTROL NO. TLM-2025-01456 (0), GT-TOLMAR,
24c. DATE RECEIVED BY MANUFACTURER 27/May/2025	24d. REPORT SOURCE <input checked="" type="checkbox"/> STUDY <input type="checkbox"/> LITERATURE <input type="checkbox"/> HEALTH PROFESSIONAL
DATE OF THIS REPORT 07/Jun/2025	25a. REPORT TYPE <input checked="" type="checkbox"/> INITIAL <input type="checkbox"/> FOLLOWUP

= Continuation attached sheet(s)..

## Continuation Sheet for CIOMS report

7+13 DESCRIBE REACTION(S) (including relevant tests/lab data) (Continuation...)

5) Pain throughout the body (General body pain (10048971), Pain (10033371)/(Mar/2025 - ) - Not Recovered/Not Resolved/Ongoing)

6) SEVERE PAIN IN ONE LEG, FROM THE WAIST DOWN (Leg pain (10024130), Pain in extremity (10033425) - Unknown)

7) GENERAL MALAISE (General malaise (10018066), Malaise (10025482)(30/Oct/2024 - ) - Not Recovered/Not Resolved/Ongoing)

Event Description :

This Study report from GUATEMALA was received by Adium (reference number: GT-ADIUM-GT-0507-20241030) on 30-OCT-2024 from a Consumer/Other Non-Health Prof regarding an Elderly 68-Year-old male patient who experienced Pain on the right side of the face, cold sensation and General malaise (Facial pain), (Feeling cold), (General malaise) during Eligard (Leuprolide acetate) 22.5 milligram therapy for Prostatic cancer. The needle component of the constituent device was not identified in the report. The report was sent to Tolmar on 31-OCT-2024.

The patient's medical history and current conditions included Prostate cancer.

Concomitant medications were not reported.

On 23-OCT-2023, the patient began receiving Eligard 22.5 milligram, q 3 month via Subcutaneous use for Prostatic cancer (Lot number and expiration date details were not provided).

On 29-OCT-2024, 1 year 7 days after the most recent dose of Eligard, the patient experienced pain on the right side of the face and took a neurobion but it gave little relief.

On 30-OCT-2024, felt a lot of pain.

On 30-OCT-2024, 1 year 8 days after the most recent dose of Eligard, the patient experienced cold sensation and general malaise.

Corrective treatment included neurobion for facial pain.

Action taken with Eligard treatment in response to the events were dose not changed, de-challenge and re-challenge were not applicable.

The outcome of Facial pain was Not Recovered/Not Resolved. The outcome of Feeling cold was Not Recovered/Not Resolved.

The outcome of General malaise was Not Recovered/Not Resolved.

The reporter did not assess the seriousness or causality of the events in relationship to Eligard.

On 06-FEB-2025, follow-up information was received by Adium (reference number: GT-ADIUM-GT-0507-20241030) from a Consumer/Other Non-Health Prof and sent to Tolmar on 07-FEB-2025.

New information included addition of non-serious events of significant pain all over his body (General body pain) and severe pain in one leg, from the waist down (Leg pain), new reporter, medical history, concomitant medication, treatment medication, most recent dose of Eligard, update to first dose date of Eligard and updated event verbatim to General malaise/patient became unwell.

The patient's medical history and current conditions included lung neoplasm malignant, drainage, and biopsy skin.

Concomitant medications included Acid (ciprofloxacin hydrochloride).

On 30-NOV-2023, the patient began receiving Eligard 22.5 milligram, q 3 month via subcutaneous use for prostatic cancer (Lot number and expiration date: not reported).

On unspecified date about 1 month ago, the patient became unwell because patient was experiencing significant pain all over his body and this pain had intensified even more because an acid was applied to the patient for his bones which was administered every 3 months, and therefore the pain continued to the present.

On unspecified date last Sunday, the patient experienced severe pain in one leg, from the waist down, and as a result, the patient was taken to a clinic where the doctor indicated that if the pain was too severe, patient would not take the medication previously prescribed (Dolgenal) because patient would need a stronger medication.

On 26-JAN-2025, patient was given a dose of morphine, and it was the only dose administered to the patient.

On 30-JAN-2025, the patient received Eligard 22.5 milligram, q 3 month via subcutaneous use (Lot number and expiration date: not reported).

Corrective treatment included Dolgenal [ketorolac tromethamine] and Tramal with tylenol (paracetamol, tramadol hydrochloride) both for body pain, and Morfina [morphine] for severe pain in one leg, from the waist down.

## Continuation Sheet for CIOMS report

Action taken with Eligard in response to the events was Dose Not Changed. De-challenge and re-challenge were not applicable.

The outcome of general body pain was Not Recovered/Not Resolved.

The outcome of general malaise was Not Recovered/Not Resolved. The outcome of leg pain was Unknown.

The reporter did not assess the seriousness of the events and assessed the causality in relationship to Eligard as Not Reported.

On 05-May-2025, follow up information was received by Adium via the PSP Solutions (Patient Support Program) (ASOFARMA A TU LADO) (reference number: GT-ADIUM-GT-0507-20241030), from a consumer. New information included: Updated clinical details of previously reported event of (pain) and added a new non-serious event of 'lung pain' (Pulmonary pain). Updated event verbatim for event malaise. The report was sent to Tolmar on 06-May-2025.

On an unknown date in Mar-2025, the patient experienced body and lung pain. No further information was available.

Corrective treatment was not reported.

Action taken with Eligard treatment in response to the events was dose not changed. De-challenge and re-challenge were not applicable.

The outcome of pulmonary pain and pain was not recovered.

The reporter did not assess the seriousness of pulmonary pain and pain.

The reporter did not provide the causality of pulmonary pain and pain in relationship to Eligard and Eligard unspecified device.

No further information is expected as consent to be contacted was not provided.

On 27-May-2025, follow up information was received by Adium via the PSP Solutions (Patient Support Program) (ASOFARMA A TU LADO) (reference number: GT-ADIUM-GT-0507-20241030), from a consumer. Report was sent to Tolmar on 28-May-2025. New information included: Case seriousness upgraded to "death", and "life threatening". New serious event "cardiorespiratory arrest" (cardio-respiratory arrest) added. Added medical history, one co-suspect drug Teoprin and two treatments for lung pain. Action taken updated from "unknown" to "not applicable".

Teoprin was considered as co-suspect, 1 a day for prostate cancer.

Medical history included prostate cancer from 6 years and lung cancer from 2 years 8 months.

Clinical history included 48 radiotherapies for prostate cancer and 9 chemotherapies.

On 09-May-2025, patient received last dose of Eligard 22.5mg every 3 months, subcutaneously for prostate cancer (Lot number and Expiration date not reported) for treatment of prostate cancer.

On 21-May-2025, patient died due to cardiorespiratory arrest and had lung pain simultaneously. The age of the patient at the time of death was unknown. It was unknown if autopsy was performed.

Corrective treatment drug includes Oxicon plus (Oxycon plus): she used 1 pill and Transtec patches: 1 every 4 days for lung pain.

Action taken with Eligard in response to the events was not applicable. De-challenge and re-challenge were not applicable.

The outcome of cardiorespiratory arrest was fatal.

The reporter assess the seriousness of cardiorespiratory arrest as serious (death)(life threatening)

The reporter did not provide the causality of cardiorespiratory arrest in relationship to Eligard and Eligard unspecified device.

No further information is expected as the reporter did not consent to be contacted for follow-up.

## Listedness

Listedness of events facial pain, pain, pain in extremity, feeling cold and malaise retained as per previous assessment.

Pulmonary pain>Eligard>Unlisted as per CCDS>07-Nov-2024

Pulmonary pain>Eligard>Unlisted as per USPI>Feb-2025

Pulmonary pain>Eligard unspecified device>Unlisted as per USPI>Feb-2025

Pulmonary pain>Eligard>Unlisted as per Canadian monograph>02-Apr-2025

Cardio-respiratory arrest>Eligard>Unlisted as per CCDS>07-Nov-2024

Cardio-respiratory arrest>Eligard>Unlisted as per USPI>Feb-2025

## Continuation Sheet for CIOMS report

Cardio-respiratory arrest>Eligard unspecified device>Unlisted as per USPI>Feb-2025  
 Cardio-respiratory arrest>Eligard>Unlisted as per Canadian monograph>02-Apr-2025

## Company Remarks (Sender's Comments) :

## Evaluator comment (Tolmar):

Causality of the previously reported events retained as per previous assessment:

Facial pain: Not related to drug and device.

Pain: Not related to drug and device.

Pain in extremity: Related to drug and not related to device.

Feeling cold: Not related to drug and device.

Malaise: Not related to drug and device.

On receipt of follow up information, regarding a patient who had pulmonary pain (lung pain) during Eligard (leuprolide acetate) 22.5 mg therapy for prostate cancer. Tolmar assessed the reported event as non-serious since it did not meet the ICH seriousness criteria and is not IME event. Event pulmonary pain was assessed as not related to Eligard (Drug and device) as the event can be explained by underlying medical history of lung neoplasm malignant.

FU- Event Cardio-respiratory arrest (Cardio-respiratory arrest) was added. Tolmar assessed the reported event as serious (Death, life threatening). Event Cardio-respiratory arrest was assessed as not related to Eligard (Drug and device) as the event can be explained by underlying medical history of lung neoplasm malignant, concomitants radiotherapy and chemotherapy.

## 14.SUSPECT DRUG(S) (Continuation...)

## Product-Reaction Level

1) Drug	: Eligard® (Leuprolide acetate)
Active Substance	: 1) Leuprolide acetate
Drug Characterization	: Suspect
Form of Admin	: 1) Injection
	2) Injection
	3) Injection
Lot Number	: 1) Unknown
	2) Unknown
	3) Unknown
Daily Dose	: (22.5 milligram(s), 1 in 3 Month)
	(22.5 milligram(s), 1 in 3 Month)
	(22.5 milligram(s), 1 in 3 Month)
Route of Admin	: 1) Subcutaneous
	2) Subcutaneous
	3) Subcutaneous
Indications	: 1) Prostatic cancer [10036946 - Prostatic cancer]
Therapy Dates	: 2) From : 30/Nov/2023 To :Not applicable
	3) From : 30/Jan/2025 To :Not applicable
Action(s) Taken With Drug	: Not applicable

## Causality

## 1) Cardiorespiratory arrest (Cardio-respiratory arrest - 10007617, Cardio-respiratory arrest - 10007617 )

Causality as per reporter : Not Reported

Causality as per Mfr : Not Related

DeChallenge : Not applicable

ReChallenge : Not Applicable

## 2) PAIN ON THE RIGHT SIDE OF THE FACE (Facial pain - 10016059, Facial pain - 10016059 )

Causality as per reporter : Not Reported

Causality as per Mfr : Not Related

DeChallenge : Not applicable

ReChallenge : Not Applicable

## 3) COLD SENSATION (Feeling cold - 10016326, Feeling cold - 10016326 )

Causality as per reporter : Not Reported

Causality as per Mfr : Not Related

DeChallenge : Not applicable

ReChallenge : Not Applicable

## 4) Lung pain (Lung pain - 10083482, Pulmonary pain - 10074693 )

Causality as per reporter : Not Reported

Causality as per Mfr : Not Related

## Continuation Sheet for CIOMS report

- DeChallenge : Not applicable  
 ReChallenge : Not Applicable
- 5) Pain throughout the body (General body pain - 10048971, Pain - 10033371 )  
 Causality as per reporter : Not Reported  
 Causality as per Mfr : Not Related  
 DeChallenge : Not applicable  
 ReChallenge : Not Applicable
- 6) SEVERE PAIN IN ONE LEG, FROM THE WAIST DOWN (Leg pain - 10024130, Pain in extremity - 10033425 )  
 Causality as per reporter : Not Reported  
 Causality as per Mfr : Related  
 DeChallenge : Not applicable  
 ReChallenge : Not Applicable
- 7) GENERAL MALAISE (General malaise - 10018066, Malaise - 10025482 )  
 Causality as per reporter : Not Reported  
 Causality as per Mfr : Not Related  
 DeChallenge : Not applicable  
 ReChallenge : Not Applicable

## Labeling :

- 1) Cardiorespiratory arrest  
 CORE UnLabeled
- 2) PAIN ON THE RIGHT SIDE OF THE FACE  
 CORE UnLabeled
- 3) COLD SENSATION  
 CORE UnLabeled
- 4) Lung pain  
 CORE UnLabeled
- 5) Pain throughout the body  
 CORE Labeled
- 6) SEVERE PAIN IN ONE LEG, FROM THE WAIST DOWN  
 CORE Labeled
- 7) GENERAL MALAISE  
 CORE Labeled
- 2) Drug : Eligard® Unspecified Device (Leuprolide acetate)  
 Active Substance : 1) Leuprolide acetate  
 Drug Characterization : Suspect  
 Form of Admin : 1) Injection  
 Lot Number : 1) Unknown  
 Indications : 1) Prostatic cancer [10036946 - Prostatic cancer]  
 Action(s) Taken With Drug : Not applicable

## Causality

- 1) Cardiorespiratory arrest (Cardio-respiratory arrest - 10007617, Cardio-respiratory arrest - 10007617 )  
 Causality as per reporter : Not Related  
 Causality as per Mfr : Not Related  
 DeChallenge : Not applicable  
 ReChallenge : Not Applicable
- 2) PAIN ON THE RIGHT SIDE OF THE FACE (Facial pain - 10016059, Facial pain - 10016059 )  
 Causality as per reporter : Not Reported  
 Causality as per Mfr : Not Related  
 DeChallenge : Not applicable  
 ReChallenge : Not Applicable
- 3) COLD SENSATION (Feeling cold - 10016326, Feeling cold - 10016326 )  
 Causality as per reporter : Not Reported  
 Causality as per Mfr : Not Related  
 DeChallenge : Not applicable  
 ReChallenge : Not Applicable
- 4) Lung pain (Lung pain - 10083482, Pulmonary pain - 10074693 )  
 Causality as per reporter : Not Reported  
 Causality as per Mfr : Not Related  
 DeChallenge : Not applicable  
 ReChallenge : Not Applicable
- 5) Pain throughout the body (General body pain - 10048971, Pain - 10033371 )  
 Causality as per reporter : Not Reported  
 Causality as per Mfr : Not Related  
 DeChallenge : Not applicable

## Continuation Sheet for CIOMS report

- ReChallenge : Not Applicable
- 6) SEVERE PAIN IN ONE LEG, FROM THE WAIST DOWN (Leg pain - 10024130, Pain in extremity - 10033425 )
- Causality as per reporter : Not Reported
- Causality as per Mfr : Not Related
- DeChallenge : Not applicable
- ReChallenge : Not Applicable
- 7) GENERAL MALAISE (General malaise - 10018066, Malaise - 10025482 )
- Causality as per reporter : Not Reported
- Causality as per Mfr : Not Related
- DeChallenge : Not applicable
- ReChallenge : Not Applicable

## Labeling :

- 1) Cardiorespiratory arrest  
CORE
- 2) PAIN ON THE RIGHT SIDE OF THE FACE  
CORE
- 3) COLD SENSATION  
CORE
- 4) Lung pain  
CORE
- 5) Pain throughout the body  
CORE
- 6) SEVERE PAIN IN ONE LEG, FROM THE WAIST DOWN  
CORE
- 7) GENERAL MALAISE  
CORE

- 3) Drug : Teoprin
- Active Substance : 1) BICALUTAMIDE
- Drug Characterization : Suspect
- Lot Number : 1) Unknown
- Daily Dose : 1) 1.0 dosage form (1 dosage form, 1 in 1 Day)
- Indications : 1) Prostate cancer [10060862 - Prostate cancer]
- Action(s) Taken With Drug : Unknown

## Causality

- 1) Cardiorespiratory arrest (Cardio-respiratory arrest - 10007617, Cardio-respiratory arrest - 10007617 )
- Causality as per reporter : Not Reported
- 2) PAIN ON THE RIGHT SIDE OF THE FACE (Facial pain - 10016059, Facial pain - 10016059 )
- Causality as per reporter : Not Reported
- 3) COLD SENSATION (Feeling cold - 10016326, Feeling cold - 10016326 )
- Causality as per reporter : Not Reported
- 4) Lung pain (Lung pain - 10083482, Pulmonary pain - 10074693 )
- Causality as per reporter : Not Reported
- 5) Pain throughout the body (General body pain - 10048971, Pain - 10033371 )
- Causality as per reporter : Not Reported
- 6) SEVERE PAIN IN ONE LEG, FROM THE WAIST DOWN (Leg pain - 10024130, Pain in extremity - 10033425 )
- Causality as per reporter : Not Reported
- 7) GENERAL MALAISE (General malaise - 10018066, Malaise - 10025482 )
- Causality as per reporter : Not Reported

## 15. DAILY DOSE(S) (Continuation...)

## Dosage Text :

Drug 1 :Eligard®

- 1) 22.5 milligram, q 3 month
- 2) 22.5 milligram, q 3 month
- 3) 22.5 milligram, q 3 month

## 22.CONCOMITANT DRUG(S) (Continuation...)

- 1). Drug : ACID 200
- Active Substance : 1) CIPROFLOXACIN HYDROCHLORIDE
- Form Strength :
- Daily Dose : 1) ( in 3 Month)

## Continuation Sheet for CIOMS report

Indications : 1) for his bones [10005956 - Bone disorder]

2). Drug : DOLGENAL [KETOROLAC TROMETHAMINE]  
 Active Substance : 1) KETOROLAC TROMETHAMINE  
 Form Strength :  
 Daily Dose : 1) (50 milligram(s))  
 Indications : 1) Body pain [10048971 - General body pain]

3). Drug : Tramal with Tylenol  
 Active Substance : 1) PARACETAMOL  
 2) TRAMADOL HYDROCHLORIDE  
 Form Strength :  
 Daily Dose : 1) (10 drop(s), in 12 Hour)  
 Indications : 1) body pain [10048971 - General body pain]  
 Therapy Dates : 1) From : 20/Nov/2024 To :

## 23. OTHER RELEVANT HISTORY (Continuation...)

- 2) RIGHT LUNG SCRAPING (10004873 , Biopsy skin) (23/Aug/2023 - ) (Continuing : NO )
- 3) RIGHT LUNG CANCER (10025044 , Lung cancer) (07/Sep/2023 - ) (Continuing : YES )
- 4) CHEMOTHERAPY (10061758 , Chemotherapy) (15/Oct/2023 - 30/Oct/2024) (Continuing : NO )
- 5) PROSTATIC CANCER (10036946 , Prostatic cancer) (Continuing : YES )
- 6) RADIOTHERAPY (10037794 , Radiotherapy)